Recent EOLS News
- Evolus to Report First Quarter Financial Results on May 7, 2024 • Business Wire • 04/23/2024 08:30:00 PM
- Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau® • Business Wire • 04/17/2024 08:05:00 PM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/12/2024 08:05:00 PM
- Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference • Business Wire • 03/26/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/11/2024 01:00:48 PM
- Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock • Business Wire • 03/11/2024 11:00:00 AM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/08/2024 09:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 09:58:20 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:42:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:09:47 PM
- Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance • Business Wire • 03/07/2024 09:05:00 PM
- Evolus Announces Results from European Head-to-Head Filler Trial • Business Wire • 03/01/2024 01:30:00 PM
- Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences • Business Wire • 02/27/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:27:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:27:32 AM
- Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024 • Business Wire • 02/22/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:37:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:37:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:37:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:36:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:36:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:35:53 PM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 02/09/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:57:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/30/2024 09:09:53 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM